Leveraging Technology to Cut Through the REMS Confusion

The Risk Evaluation and Mitigation Strategies (REMS) program has taken center stage recently as the Food and Drug Administration (FDA), pharmacies and healthcare providers seek ways to improve and streamline its administration. Created in 2007 as part of the FDA Amendments Act, REMS was designed to ensure that the benefits of a drug or biological product outweigh its risks, as well as for post-marketing surveillance of medication safety. While providers agree with these goals, many are also concerned with issues they believe are preventing REMS from achieving its objectives.

Download White Paper

You may also like:

Blog Post

Adverse drug reactions from antibiotic exposure occur in one out of every five patients, according to two large studies of patients in the community and hospitalized patients, respectively. The community study measured emerge...

View Blog Post
Blog Post

The American Society of Automation in Pharmacy’s (ASAP) Midyear Conference brought more than 100 key technology executives together for three days of learning in Palm Beach, Florida. Thro...

View Blog Post
Blog Post

Medication errors are on the rise, particularly those that occur in the home, according to a recent study published in Clinical Toxicology. By analyzing data collected...

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up